Rapid Micro Biosystems (NASDAQ:RPID) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Rapid Micro Biosystems (NASDAQ:RPID) announced its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05), FiscalAI reports. Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. The firm had revenue of $11.28 million during the quarter, compared to analysts’ expectations of $10.93 million.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Rapid Micro reported a record Q4 with $11.3 million revenue (up 37% YoY) and placed 16 Growth Direct systems in the quarter, finishing 2025 with 190 systems placed (155 fully validated).
• Management set 2026 guidance of $37–$41 million revenue and 30–38 system placements, targeting approximately 20% full‑year gross margin with a Q4 exit in the mid‑20s%, signaling expected margin expansion and growth cadence.
• Q4 product margin was weighed down by a $1.1 million write‑off of unusable consumable inventory, producing a negative overall gross margin for the quarter and contributing to a Q4 net loss of $12.5 million.
• The MilliporeSigma collaboration is progressing (customer demo labs in Europe and Asia) and management says recent procurement agreements and supply‑chain actions will drive meaningful consumable cost reductions that should accelerate gross‑margin improvement in H2 2026.
• Rapid Micro plans a next‑generation cloud‑native software platform with AI analytics in H2 2026 to enable fleet‑level insights and potential higher‑margin services, but monetization timing and scale remain uncertain.

Rapid Micro Biosystems Trading Down 12.8%

Shares of RPID stock opened at $3.82 on Thursday. Rapid Micro Biosystems has a fifty-two week low of $1.86 and a fifty-two week high of $4.94. The company has a 50 day moving average price of $3.97 and a 200 day moving average price of $3.54. The stock has a market capitalization of $169.35 million, a P/E ratio of -3.78 and a beta of 1.38. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 4.23.

Insiders Place Their Bets

In other Rapid Micro Biosystems news, CFO Sean M. Wirtjes sold 17,254 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $3.92, for a total value of $67,635.68. Following the completion of the transaction, the chief financial officer owned 563,674 shares of the company’s stock, valued at $2,209,602.08. This trade represents a 2.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Robert G. Jr. Spignesi sold 38,327 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $3.89, for a total transaction of $149,092.03. Following the completion of the transaction, the chief executive officer owned 1,187,770 shares of the company’s stock, valued at approximately $4,620,425.30. This trade represents a 3.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 214,700 shares of company stock worth $873,906 in the last ninety days. 29.96% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RPID. American Century Companies Inc. grew its stake in Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after purchasing an additional 5,341 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Rapid Micro Biosystems in the 4th quarter valued at about $71,000. Barclays PLC acquired a new stake in Rapid Micro Biosystems in the 4th quarter valued at about $72,000. XTX Topco Ltd purchased a new position in shares of Rapid Micro Biosystems in the 2nd quarter valued at about $144,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Rapid Micro Biosystems in the 4th quarter valued at about $160,000. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RPID has been the subject of a number of research reports. Wall Street Zen raised Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.